Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MVO | Mv Oil Trust | $3.03 | $0.96 | 46.38% | 3.1M | $24M | $0.97$6.60 |
| RLYB | Rallybio | $10.97 | $3.43 | 45.49% | 3.7M | $40M | $1.76$11.20 |
| AURE | Aurelion | $2.29 | $0.67 | 41.36% | 1.3M | $56M | $1.50$14.60 |
| RCAX | Tidal Trust II - Defiance Daily Target 2x Long Rcat ETF | $17.63 | $4.47 | 33.91% | 705.3K | - | $11.66$22.31 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $3.12 | $0.72 | 30.00% | 43.1M | - | $0.95$20.92 |
| ASTH | Astrana Health | $26.32 | $5.99 | 29.46% | 142.4K | $1.0B | $18.08$34.80 |
| DBGI | Digital Brands Group | $3.71 | $0.84 | 29.27% | 1.2M | $24M | $1.77$18.00 |
| ANNA | AleAnna | $3.64 | $0.79 | 27.72% | 337.1K | $116M | $2.31$18.30 |
| EMAT | Evolution Metals & Technologies | $10.11 | $2.14 | 26.85% | 21.4K | $23M | $5.50$24.37 |
| JFB | Jfb Construction | $18.92 | $3.75 | 24.72% | 6.9K | $96M | $3.39$35.10 |
| CGEN | Compugen | $2.25 | $0.44 | 24.31% | 2.1M | $169M | $1.13$2.38 |
| ALMU | Aeluma | $19.13 | $3.66 | 23.66% | 78.9K | $279M | $5.79$25.88 |
| CTNT | Cheetah Net Supply Chain Service | $2.09 | $0.39 | 22.94% | 468.4K | $5.6M | $1.03$2.31 |
| OCUL | Ocular Therapeutix | $10.98 | $2.04 | 22.82% | 17.2M | $1.9B | $5.79$16.44 |
| AXTI | AXT | $46.50 | $8.60 | 22.69% | 549.8K | $2.1B | $1.13$47.00 |
| AAOI | Applied Optoelectronics | $102.46 | $18.23 | 21.64% | 1.1M | $5.8B | $9.71$110.00 |
| MGN | Megan | $2.43 | $0.43 | 21.50% | 636.1K | $33M | $1.00$8.63 |
| NUCL | Eagle Nuclear Energy | $5.83 | $1.02 | 21.08% | 613.4K | $48M | $4.55$9.65 |
| LASR | nLIGHT | $67.99 | $11.80 | 21.00% | 226.2K | $3.1B | $6.20$68.14 |
| SYPR | Sypris Solutions | $3.56 | $0.60 | 20.27% | 275K | $68M | $1.42$4.74 |
| USGO | U.s. GoldMining | $14.47 | $2.43 | 20.13% | 20.9K | $160M | $7.42$17.98 |
| NEOV | NeoVolta | $3.46 | $0.57 | 19.72% | 1.6M | $123M | $1.80$7.13 |
| LSE | Leishen Energy | $5.49 | $0.89 | 19.35% | 388K | $78M | $3.80$14.99 |
| PURR | Hyperliquid Strategies | $4.86 | $0.78 | 19.12% | 7.1M | $506M | $3.01$5.78 |
| VIAV | Viavi Solutions | $35.34 | $5.63 | 18.95% | 500.4K | $6.9B | $8.10$35.61 |
Related Articles
Featured Article
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
George Budwell, PhD|Jan 3, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
This Exciting Biopharma Could Earn You 55% in 12 Months
Jeffrey Little|Aug 22, 2021
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
Cory Renauer|Aug 21, 2021
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Can Ocular Therapeutix Reach Its Full Potential?
Brian Orelli, PhD and Keith Speights|Apr 1, 2021
The biotech has a ways to go.
![Can_Ocular_Therapeutix_Reach_Its_Full_Potential[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619459%2Fcan_ocular_therapeutix_reach_its_full_potential1.jpg&w=384&op=resize)
3 Top Healthcare Stocks to Buy Now
Cory Renauer|Feb 17, 2021
Find out how shares of these disruptive businesses could make you rich.
3 Reasons to Buy Ocular Therapeutix Stock Right Now
Cory Renauer|Feb 16, 2021
There are a few reasons this could be the best biotech stock you can buy at the moment.
3 Top 5G Stocks to Buy in September
5G networks have made nationwide debuts, but these hardware stocks could have the most to gain.
2 Top Biotech Picks for May
Zhiyuan Sun|May 20, 2020
Here are the hottest companies coming up in the biotech sector.
Can This Biotech Shed New Light on Cancer Immunotherapies?
Zhiyuan Sun|May 4, 2020
Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.
